This integrated, machine learning‐driven approach [28] allowed us to pinpoint IGFBP7 as a key regulator, highlighting its potential as a predictive biomarker and therapeutic target for improving STAD management. The gene discussed is IGFBP7; the disease is gastric adenocarcinoma.